www.fdanews.com/articles/85322-morphosys-and-japanese-pharmaceutical-group-daiichi-sankyo-form-broad-alliance-to-develop-novel-antibody-therapies
MORPHOSYS AND JAPANESE PHARMACEUTICAL GROUP DAIICHI SANKYO FORM BROAD ALLIANCE TO DEVELOP NOVEL ANTIBODY THERAPIES
March 16, 2006
MorphoSys AG today announced that Sankyo Company, Limited, a wholly owned subsidiary of Daiichi Sankyo Company, Limited, and MorphoSys AG have entered into a license agreement and therapeutic antibody collaboration for an initial two-year term with the option of an extension of up to three more years.